ArticleCancer reports (Hoboken, N.J.)2025
Incidence and Clinical Outcomes of Vitamin D Status and Myeloma Bone Disease Among Patients With Newly Diagnosed Multiple Myeloma (MM) in a Tropical Country-Retrospective Cohort Study.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe retrospective data analysis on 80 patients from 2018 to 2022 aimed to determine the incidence and clinical outcomes of vitamin D status and myeloma bone disease among newly diagnosed multiple myeloma (MM) patients in Singapore.
methodPatients' demographics, bone health data and bone disease management were collected. Chi-square test was conducted to compare variables between patients who survived versus those who demised. Survival differences were compared using log-rank analysis and plotted using Kaplan-Meier estimates. Multivariable survival analysis was conducted using Cox Regression.
resultsFifty-nine (73.8%) patients had myeloma bone disease at diagnosis, and 42 (71.2%) of these patients had skeletal-related adverse events at diagnosis. The compliance to bone health management needs to be optimized, as only 70 patients had their vitamin D level tested at diagnosis, of which 48 (68.7%) patients were vitamin D insufficient or deficient. Bone disease data did not correlate with mortality. Higher mortality was initially observed among patients with non-Chinese (p = 0.03), R-ISS 3 (p = 0.001), and renal involvement at diagnosis (p = 0.035). R-ISS staging remained the only statistically significant variable after adjusting for race (adjusted HR 3.99; 95% CI 1.58-10.07).
conclusionThe study found no correlation between myeloma bone health data and survival outcomes in our centre.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.